Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 10, 2006

CombiMatrix Test Discriminates Malignant Melanoma from Benign Moles

  • CombiMatrix Molecular Diagnostics launched a new test that discriminates malignant melanoma from benign moles. The test based on CombiMatrix’ CustomArray® platform, enables pathologists to resolve difficult-to-diagnose cases through an objective genetic analysis.

    “This exciting new test represents a breakthrough in the field of dermatology,” says Scott Binder, M.D., a member of the company’s scientific advisory board. “As a dermatopathologist I am often called upon to make very difficult decisions regarding whether or not a patient has malignant melanoma, particularly after traditional laboratory methods have failed to provide a clear diagnosis. This test from CombiMatrix molecular diagnostics provides me with a powerful new tool to help resolve many of these tough cases.”



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »